These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1355 related articles for article (PubMed ID: 20965785)

  • 1. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
    Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
    Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
    Valent P
    Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
    [No Abstract]   [Full Text] [Related]  

  • 7. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
    Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
    Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
    Thielen N; van der Holt B; Cornelissen JJ; Verhoef GE; Gussinklo T; Biemond BJ; Daenen SM; Deenik W; van Marwijk Kooy R; Petersen E; Smit WM; Valk PJ; Ossenkoppele GJ; Janssen JJ
    Eur J Cancer; 2013 Oct; 49(15):3242-6. PubMed ID: 23876833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
    Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
    Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
    Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
    Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
    Etienne G; Guilhot J; Rea D; Rigal-Huguet F; Nicolini F; Charbonnier A; Guerci-Bresler A; Legros L; Varet B; Gardembas M; Dubruille V; Tulliez M; Noel MP; Ianotto JC; Villemagne B; Carré M; Guilhot F; Rousselot P; Mahon FX
    J Clin Oncol; 2017 Jan; 35(3):298-305. PubMed ID: 28095277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.